Frontiers in endocrinology · 2026
Nonlinear association of serum uric acid and C-peptide with arterial stiffness in patients with type 2 diabetes: a real-world study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
He Youming, Jin Yufeng, Gao Mengqi, Jin Jing, Chen Ke, Zhou Lixin, Shi Jingbin, Luo Bei, Liang Yongqian
Аннотация
BACKGROUND: Diabetes has become one of the most serious and prevalent chronic diseases, and its cardiovascular complications are responsible for over 50% of diabetes-related deaths. However, the relationships between uric acid (UA) and C-peptide on arterial stiffness (AS) in patients with type 2 diabetes mellitus (T2DM) are still poorly understood. This study aimed to evaluate the associations between UA and C-peptide with AS in T2DM patients.
METHODS: In this cross-sectional study of 1,715 participants with T2DM, we recorded levels of fasting UA, C-peptide, and other characteristics. Elevated AS was defined as a brachial-ankle pulse wave velocity (baPWV) of ≥1,400 cm/s. Logistic regression and a restricted cubic spline (RCS) model were employed to assess the associations of UA and C-peptide with AS.
RESULTS: Fasting UA and C-peptide levels were independently and significantly associated with elevated AS in patients with T2DM, as determined by multivariate analyses (P < 0.05). Notably, RCS analyses revealed nonlinear relationships with threshold effects between fasting UA, C-peptide, and elevated AS (P for nonlinearity < 0.05). Compared to patients with C-peptide levels < 0.580 μg/L, those with levels ≥ 0.580 μg/L had an approximately 87% relatively higher odds of elevated AS (OR = 1.87, 95% CI: 1.32, 2.65).
CONCLUSION: The elevated AS odds in patients with T2DM were nonlinearly associated with the levels of serum fasting UA and C-peptide.
METHODS: In this cross-sectional study of 1,715 participants with T2DM, we recorded levels of fasting UA, C-peptide, and other characteristics. Elevated AS was defined as a brachial-ankle pulse wave velocity (baPWV) of ≥1,400 cm/s. Logistic regression and a restricted cubic spline (RCS) model were employed to assess the associations of UA and C-peptide with AS.
RESULTS: Fasting UA and C-peptide levels were independently and significantly associated with elevated AS in patients with T2DM, as determined by multivariate analyses (P < 0.05). Notably, RCS analyses revealed nonlinear relationships with threshold effects between fasting UA, C-peptide, and elevated AS (P for nonlinearity < 0.05). Compared to patients with C-peptide levels < 0.580 μg/L, those with levels ≥ 0.580 μg/L had an approximately 87% relatively higher odds of elevated AS (OR = 1.87, 95% CI: 1.32, 2.65).
CONCLUSION: The elevated AS odds in patients with T2DM were nonlinearly associated with the levels of serum fasting UA and C-peptide.